Differential effects of lercanidipine/enalapril versus amlodipine/enalapril and hydrochlorothiazide/enalapril on target organ damage and sympathetic activation in non-obese essential hypertensive subjects

References

• Poulter NR, Prabhakaran D, Caulfield M. Hypertension. Lancet 2015;86:801-12
   Web of Science ®Google Scholar
• Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005;365:217-23
   PubMed Web of Science ®Google Scholar
• Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013;31:1281-357
   Google Scholar
• Chrysant SG. Using fixed-dose combination therapies to achieve blood pressure goals. Clin Drug Investig 2008;28:713-34
   PubMed Web of Science ®Google Scholar
• Borghi C, Cicero AF. Rationale for the use of a fixed-dose combination in the management of hypertension: efficacy and tolerability of lercanidipine/enalapril. Clin Drug Investig 2010;30:843-54
   PubMed Web of Science ®Google Scholar
• Hair PI, Scott LJ, Perry CM. Fixed-dose combination lercanidipine/enalapril. Drugs 2007;67:95-106
   PubMed Web of Science ®Google Scholar
• Arnaout S; DUAL Investigators Study Group. Efficacy and safety of lercanidipine/enalapril fixed combination in Lebanon: a prospective observational study. Curr Med Res Opin 2015;31:187-90
   PubMed Web of Science ®Google Scholar
• Maldonado J, Pereira T, Tavares A. Efficacy and safety of a lercanidipine/enalapril fixed-dose combination in hypertensive patients in Portugal. Drugs R D 2014;14:147-54
   PubMedGoogle Scholar
• Epstein M. Lercanidipine: a novel dihydropyridine calcium-channel blocker. Heart Dis 2001;3:398-407
   PubMedGoogle Scholar
• Robles NR, Ocon J, Gomez Campdera F, et al. Lercanidipine in chronic renal failure patients: the ZAFRA study. Ren Fail 2005;27:73-80
   PubMed Web of Science ®Google Scholar
• Robles NR, Romero B, de Vinuesa EG, et al. Treatment of proteinuria with lercanidipine associated with renin-angiotensin axis-blocking drugs. Ren Fail 2010;32:192-7
   PubMed Web of Science ®Google Scholar
• Todd PA, Goa KL. Enalapril. A reappraisal of its pharmacology and therapeutic use in hypertension. Drugs 1992;43;346-81
   PubMed Web of Science ®Google Scholar
• Ravid M, Brosh D, Levi Z, et al. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 1998;128:982-8
   PubMed Web of Science ®Google Scholar
• Hosomi N, Mizushige K, Ohyama H et al. Angiotensin-converting enzyme inhibition with enalapril slows progressive intimamedia thickening of the common carotid artery in patients with non-insulin-dependent diabetes mellitus. Stroke 2001;32:1539-45
   PubMed Web of Science ®Google Scholar
• De Ciuceis C, Salvetti M, Rossini C, et al. Effect of antihypertensive treatment on microvascular structure, central blood pressure and oxidative stress in patients with mild essential hypertension. J Hypertens 2014;32:565-74
   PubMed Web of Science ®Google Scholar
• Derosa G, Bonaventura A, Romano D, et al. Effects of enalapril/lercanidipine combination on some emerging biomarkers in cardiovascular risk stratification in hypertensive patients. J Clin Pharm Ther 2014;39:277-85
   PubMed Web of Science ®Google Scholar
• Mancia G, Coca A, Chazova I, et al.; on behalf of the FELT Investigators. Effects on office and home blood pressure of the lercanidipine–enalapril combination in patients with stage 2 hypertension: a European randomized controlled clinical trial. J Hypertens 2014;32:1700-7
   Google Scholar
• Mancia G, Omboni S, Chazova I, et al. Effects of lercanidipine–enalapril combination vs the corresponding monotherapies on home blood pressure in hypertension. Evidence from a large database. J Hypertens 2016;34:139-48
   Google Scholar
• Tsioufis C, Dimitriadis K, Selima M, et al. Low-grade inflammation and hypoadiponectinaemia have an additive detrimental effect on aortic stiffness in essential hypertensive patients. Eur Heart J 2007;28:1162-9
   PubMed Web of Science ®Google Scholar
• Tsioufis C, Dimitriadis K, Thomopoulos C, et al. Exercise blood pressure response, albuminuria, and arterial stiffness in hypertension. Am J Med 2008;121:894-902
   PubMed Web of Science ®Google Scholar
• O’Rourke MF, Gallagher DE. Pulse wave analysis. J Hypertens 1996;14:S147-S57
   PubMed Web of Science ®Google Scholar
• Wan L, Yang N, Hiew CY, et al. An assessment of the accuracy of renal blood flow estimation by Doppler ultrasound. Intensive Care Med 2008;34:1503-10
   PubMed Web of Science ®Google Scholar
• Saif A, Soliman NA, Abdel-Hameed A. Early evaluation of renal hemodynamic alterations in type I diabetes mellitus with duplex ultrasound. Saudi J Kidney Dis Transpl 2010;21:295-9
   PubMedGoogle Scholar
• Seravalle G, Dimitriadis K, Dell’Oro R, et al. How to assess sympathetic nervous system activity in clinical practice. Curr Clin Pharmacol 2013;8:182-8
   PubMedGoogle Scholar
• Sabbatini M, Leonardi A, Testa R, et al. Effect of calcium antagonists on glomerular arterioles in spontaneously hypertensive rats. Hypertension 2000;35:775-9
   PubMed Web of Science ®Google Scholar
• Cauwenberghs N, Kuznetsova T. Determinants and prognostic significance of the renal resistive index. Pulse (Basel) 2016;3:172-8
   PubMedGoogle Scholar
• Tsioufis C, Tatsis I, Thomopoulos C, et al. Effects of hypertension, diabetes mellitus, obesity and other factors on kidney haemodynamics. Curr Vasc Pharmacol 2014;12:537-48
   PubMed Web of Science ®Google Scholar
• Tsioufis C, Dimitriadis K, Antoniadis D, et al. Inter-relationships of microalbuminuria with the other surrogates of the cardiovascular disease in hypertensive subjects. Am J Hypertens 2004;17:470-6
   PubMed Web of Science ®Google Scholar
• Fok H, Cruickshank JK. Future treatment of hypertension: shifting the focus from blood pressure lowering to arterial stiffness modulation? Curr Hypertens Rep 2015;17:67
   PubMed Web of Science ®Google Scholar
• Papademetriou V, Katsiki N, Doumas M, et al. Halting arterial aging in patients with cardiovascular disease: hypolipidemic and antihypertensive therapy. Curr Pharm Des 2014;20:6339-49
   PubMed Web of Science ®Google Scholar
• Koumaras C, Tziomalos K, Stavrinou E, et al. Effects of renin–angiotensin–aldosterone system inhibitors and beta-blockers on markers of arterial stiffness. J Am Soc Hypertens 2014;8:74-82
   PubMed Web of Science ®Google Scholar
• Seravalle G, Brambilla G, Pizzalla DP, et al. Differential effects of enalapril–felodipine versus enalapril–lercanidipine combination drug treatment on sympathetic nerve traffic and metabolic profile in obesity-related hypertension. J Am Soc Hypertens 2016;10:244-51
   PubMed Web of Science ®Google Scholar